Clinically, BC is classified based on the initial morphological assessment of the tumor (type, size, grade, lymph node status), and more recently, on the basis of the expression of receptors of estrogen (ER), progesterone (PR) and human epidermal growth factor 2 (ERBB2/HER2). This evidence concerns the gene ERBB2 and neoplasm.